This company has been acquired
TARO Stock Overview
A science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Taro Pharmaceutical Industries Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.97 |
| 52 Week High | US$45.76 |
| 52 Week Low | US$32.67 |
| Beta | 0.56 |
| 1 Month Change | 0.66% |
| 3 Month Change | 1.97% |
| 1 Year Change | 10.21% |
| 3 Year Change | -40.56% |
| 5 Year Change | -50.36% |
| Change since IPO | 759.40% |
Recent News & Updates
Recent updates
Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity
Dec 12Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)
Aug 16Taro Pharmaceutical: Potential Value In Sun Pharma Offer
Jun 02Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold
Feb 24Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M
Jan 24Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M
Oct 28Taro Pharmaceutical hits 52-week low; down 28% YTD
Aug 15Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M
Jul 27Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card
Jul 14We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative
Aug 03
A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns
Jan 26
Shareholder Returns
| TARO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.4% | 3.0% | 2.8% |
| 1Y | 10.2% | 8.9% | 24.6% |
Return vs Industry: TARO underperformed the US Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: TARO underperformed the US Market which returned 24.1% over the past year.
Price Volatility
| TARO volatility | |
|---|---|
| TARO Average Weekly Movement | 0.6% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TARO has not had significant price volatility in the past 3 months.
Volatility Over Time: TARO's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 1,554 | Uday Baldota | www.taro.com |
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.
Taro Pharmaceutical Industries Ltd. Fundamentals Summary
| TARO fundamental statistics | |
|---|---|
| Market cap | US$1.62b |
| Earnings (TTM) | US$53.87m |
| Revenue (TTM) | US$629.18m |
30.0x
P/E Ratio2.6x
P/S RatioIs TARO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TARO income statement (TTM) | |
|---|---|
| Revenue | US$629.18m |
| Cost of Revenue | US$324.20m |
| Gross Profit | US$304.98m |
| Other Expenses | US$251.11m |
| Earnings | US$53.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.43 |
| Gross Margin | 48.47% |
| Net Profit Margin | 8.56% |
| Debt/Equity Ratio | 0% |
How did TARO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/24 10:55 |
| End of Day Share Price | 2024/06/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Taro Pharmaceutical Industries Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Randall Stanicky | Goldman Sachs |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Kenneth Cacciatore | TD Cowen |